Reading the tape
NASDAQ: BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
Market Cap
$29.22B
52w High
$202.41
52w Low
$119.18
P/E
21.23
Volume
1.54M
Outstanding Shares
147.64M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
1Y Price: 59.12%Revenue (TTM): 0.42%FCF (TTM): 14.27%P/FCF: 35th pct
What changed
The stock rose 59.12% over the last year. Revenue grew 0.42% over the trailing twelve months. Operating margin moved from 22.26% to 15.65%. Free cash flow grew 14.27% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 15.65%. A decisive move in revenue — currently up 0.42% — would be the clearest signal to resolve the ambiguity.
Company profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
CEOChristopher A. Viehbacher
SectorHealthcare
IndustryDrug Manufacturers - General
Employees7,605
IPO dateSep 17, 1991
Valuation
Forward P/E—
EV/EBITDA9.60
Enterprise value$29.76B
Stock splits
Jan 18, 2001↑ Forward
Every 1 shares became 3
Dec 21, 1999↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth1.93%
Gross margin69.77%▼7.42%vs FY2024
Operating margin15.65%▼25.64%vs FY2024
ROE7.08%▼27.45%vs FY2024
Analyst consensus
RatingBuy
Target price$211.42▲6.80%
28
Buy
19
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jul 30, 2026
Q3 FY26 · EPS est $3.33 · Revenue est $2.43B
View